Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin.
Gelatin has been used as shell polymer in the manufacture of soft gelatin capsules (softgels) for about the past century. Its rheological and thermal properties offer adequate balance for subsequent process steps including gel solution preparation/transportation, film casting, and capsule sealing/drying.
Even though this material represents the current gold standard for soft capsules, it presents certain technical challenges such as cross-linking. In other words, it may react with some capsule active fills during storage, leading to a delay in the release time. Moreover, gelatin-based soft capsules are sensitive to heat during production, as well as during storage. Finally, both the cross-linking tendency and heat sensitivity limit the options for fill materials, especially those requiring higher processing temperatures.
Multiple vegetal origin materials were investigated as potential replacement for gelatin. Various modified starches (corn, tapioca, etc.), alone or in combination with some hydrocolloids (carrageenan, alginates, gellan gum, etc.) were used to develop non-gelatin shell formulations over the last two decades. Some of the existing commercial options are associated with important initial investment such as the need to modify the equipment (tumble dryers, etc.), or to buy special feature parts (gel mixer, spreader boxes, etc.). From a process standpoint, they are also often associated with limitations such as lower production speed, longer drying time, and capsule defects like leakage or stickiness in comparison with gelatin.
Riding the wave of sustainability, “vegan” or “clean label,” pharmaceutical and nutraceutical companies are now trying to combine the best of both worlds. Actually, they are looking at vegetarian alternatives that display similar or even higher technical performance than gelatin for the production of soft capsules: using standard equipment at full speed, to deliver optimal capsules with additional fill material options and better stability.
See the full white paper here.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...